

# Stefanie Jilg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8030827/publications.pdf>

Version: 2024-02-01

9  
papers

324  
citations

1477746

6  
h-index

1473754

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

704  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103197.	0.5	2
2	Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 148, 331.	1.2	2
3	Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis. <i>European Journal of Haematology</i> , 2020, 104, 125-137.	1.1	5
4	Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. <i>Nature</i> , 2020, 588, 157-163.	13.7	90
5	Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. <i>Experimental Hematology and Oncology</i> , 2019, 8, 9.	2.0	36
6	Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST). <i>International Journal of Cancer</i> , 2019, 145, 2292-2303.	2.3	21
7	Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile. <i>Oncotarget</i> , 2018, 9, 17270-17281.	0.8	18
8	RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. <i>Cancer Cell</i> , 2016, 30, 75-91.	7.7	144
9	Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study. <i>Leukemia and Lymphoma</i> , 2015, 56, 3227-3229.	0.6	6